425: AlloVir and Kalaris Therapeutics Announce Merger to Advance Novel Retinal Disease Treatment

AlloVir and Kalaris Therapeutics have agreed to merge, combining their resources to develop Kalaris's lead asset, TH103, a potential best-in-class anti-VEGF therapy for retinal diseases.

Summary

• AlloVir and Kalaris Therapeutics have entered into a merger agreement, with Kalaris becoming a wholly-owned subsidiary of AlloVir.
• The merger aims to combine AlloVir's resources with Kalaris's expertise in retinal disease treatments, particularly the development of TH103.
• The implied ownership split post-combination is 74.95% for Kalaris and 25.05% for AlloVir, without considering any bridge financing.
• Kalaris is valued at $347 million, while AlloVir is valued at $116 million, assuming approximately $100 million in cash at closing.
• The combined company is expected to be renamed Kalaris Therapeutics, Inc. and will trade on NASDAQ under the ticker symbol KLRS.
• A bridge note financing of up to $15 million is expected, with $7.5 million from existing Kalaris stockholders and $7.5 million from AlloVir.
• The combined company's cash is expected to fund operations into Q4 2026.
• The merger is expected to close in Q1 2025, subject to stockholder approval and other customary closing conditions.
• The combined company will be led by Kalaris's current CEO, Andrew Oxtoby, and the board will be chaired by AlloVir's current chair, David Hallal.
• Kalaris's lead asset, TH103, is a fusion protein targeting VEGF, with potential for longer-acting and increased anti-VEGF activity compared to existing treatments.
• A Phase 1 clinical trial for TH103 in nAMD is currently enrolling, with initial data expected in Q3 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the merger's potential to advance a promising new therapy, TH103, with strong preclinical data and a large market opportunity. However, there are inherent risks associated with clinical development and the need for future capital raises.

Positives

• The merger combines the resources of AlloVir with Kalaris's expertise in retinal disease treatments.
• TH103 has the potential to be a best-in-class anti-VEGF therapy due to its longer-acting and increased anti-VEGF activity.
• Preclinical data suggests TH103 has superior efficacy and duration compared to existing treatments like aflibercept.
• The combined company is expected to have sufficient cash to fund operations into Q4 2026.
• The management team and board have extensive experience in developing and commercializing retina therapeutics.
• The global anti-VEGF market is large and growing, indicating a significant commercial opportunity for TH103.
• TH103 has strong intellectual property protection with patents issued in multiple countries and exclusivity through the early 2040s in the US.

Negatives

• The merger is subject to stockholder approval and other customary closing conditions, which could delay or prevent the transaction.
• There are risks associated with the clinical development and regulatory approval of TH103, including potential delays in clinical trials.
• The combined company will need to raise additional capital to continue advancing TH103 and other product candidates.
• There are uncertainties regarding the market price of AlloVir's common stock relative to the value suggested by the exchange ratio.
• The combined company faces competition from other companies developing anti-VEGF therapies.
• Suboptimal real-world outcomes are common with current anti-VEGF treatments due to undertreatment and onerous visit regimens.

Risks

• The merger may not be completed if conditions to closing are not satisfied, including obtaining stockholder approval.
• There are risks related to managing operating expenses and expenses associated with the merger.
• The combined company may not be able to obtain sufficient additional capital to continue advancing product candidates.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• The combined company may face competitive responses to the merger.
• There is a risk of litigation, including securities class action litigation, that could divert management's attention and harm the business.
• The bridge financing may not be consummated prior to the closing.

Future Outlook

The combined company plans to advance TH103 through clinical trials, with initial Phase 1 data expected in Q3 2025 and Phase 2 initiation in 1H 2026. The company also plans to expand into other VEGF-mediated retinal diseases.

Management Comments

• The combined company will be led by current Kalaris CEO, Andrew Oxtoby.
• Post-closing Board of Directors to be led by current AlloVir Chair, David Hallal.

Industry Context

The merger comes as the anti-VEGF market for retinal diseases is growing, with a significant unmet need for longer-acting and more effective treatments. The combination of AlloVir and Kalaris aims to address this need with TH103, a next-generation anti-VEGF therapy.

Comparison to Industry Standards

• Current anti-VEGF therapies like aflibercept and ranibizumab require frequent injections, often every 1-2 months, leading to undertreatment and suboptimal real-world outcomes.
• TH103 is designed to have longer-acting and increased anti-VEGF activity, potentially reducing the frequency of injections and improving patient outcomes.
• Preclinical studies show TH103 achieved 100% inhibition of VEGF-induced endothelial cell proliferation compared to 80% by aflibercept, suggesting superior efficacy.
• TH103 demonstrated increased retinal retention and duration of action in animal models compared to aflibercept, indicating a potential for longer treatment effect.
• The global anti-VEGF market is dominated by branded products like aflibercept and ranibizumab, with a growing market for biosimilars and new therapies like faricimab.

Management Changes

Stakeholder Impact

• Shareholders of both AlloVir and Kalaris will be impacted by the merger, with Kalaris shareholders owning a larger portion of the combined company.
• Employees of both companies will be affected by the integration of the two organizations.
• Patients with retinal diseases may benefit from the development of TH103, a potential new treatment option.
• The merger could impact competitors in the anti-VEGF market.

Next Steps

• Obtain stockholder approval for the merger.
• Complete the bridge note financing.
• Close the merger in Q1 2025.
• Continue enrollment in the Phase 1 clinical trial of TH103.
• Announce initial Phase 1 clinical trial data in Q3 2025.
• Initiate the Phase 2 clinical trial of TH103 in 1H 2026.

Key Dates

Keywords

Merger, AlloVir, Kalaris Therapeutics, TH103, Anti-VEGF, Retinal Diseases, nAMD, Clinical Trial, Biopharmaceutical, Ophthalmology